Pfizer Ltd’s shares surged 5.4% to ₹5,385 in early trade on Thursday after the pharmaceutical company reported robust first-quarter results for FY26. The company’s net profit grew 27.2% year-on-year (YoY) to ₹191.7 crore, up from ₹150.7 crore in Q1 FY25, supported by margin expansion and a one-time gain from asset sales.
Revenue from operations stood at ₹604 crore, marking a 7.1% YoY rise compared to ₹564 crore in the year-ago period. Operating performance was strong, with EBITDA climbing 18.1% to ₹209.7 crore from ₹177.6 crore last year. EBITDA margins improved to 34.8% from 31.5% in Q1 FY25, reflecting better operational efficiency.
The quarter’s results were boosted by an exceptional gain of ₹172.81 crore from the transfer of MIDC land and building. Management highlighted that excluding this exceptional income, core business performance still showed healthy growth driven by steady product demand and cost control.
Earlier this week, Pfizer announced the launch of its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, enhancing its vaccine portfolio and tapping into a wider preventive healthcare market.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
